An innovative clinical trial is set to commence in Australia testing whether a common blood thinning drug can prevent SARS-CoV-2 infection. The drug is administered by nasal spray and researchers believe it can block the virus from initially infecting cells in the nose.
PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.